Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 4Tumor-Agnostic 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × 2-Propanol × 1 year × Clear all
NCT04181463 2026-05-27

Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
112 enrolled
Tumor-Agnostic

Neoplasms

NCT03728335 2026-05-20

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05441514 2026-05-05

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Completed
3 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04203316 2026-01-09

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Children's Oncology Group

Phase 2 Active not recruiting
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡